ClinicalTrials.gg
RecruitingNCT06533228Updated Oct 27, 2025

Helmsley 3.0: Abbreviated MRE

An observational study in Crohn's Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 2 sites in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati — 3 open to participants now, 4 under way, 1 of them phase 3. Crohn Disease · Children's Hospital Medical Center, Cincinnati.

Started
2024
the only one that year
Observational
6 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2024, is one of 6 observational ones, and was the 14th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

The purpose of our study is to compare an abbreviated magnetic resonance imaging (MRI) of the bowel or magnetic resonance enterography (MRE) protocol to a conventional, standard of care MRE in children and adults with Crohn's Disease.

Read the detailed description

This multi-center study will evaluate the effectiveness of an abbreviated magnetic resonance imaging (MRI) of the bowel or magnetic resonance enterography (MRE) to document the presence and severity of small bowel inflammation, the presence and features of stricturing and penetrating disease in children and adults with Crohn's Disease.

The abbreviated MRI of the bowel or MRE will not involve IV contrast or an injection of glucagon and water will replace the oral contrast used in standard of care MREs. Scan time will be greatly reduced with the abbreviated MRE ( approximately 15 minutes) compared to a standard of care MRE (approximately 60 minutes).

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Magnetic Resonance Imaging (MRI)
  • Crohn's Disease
  • Magnetic Resonance Enterography (MRE)
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children and adults

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established Crohn's disease diagnosis in patients 10 and older
  • Undergoing clinical magnetic resonance enterography (MRE) examinations for any reason(s) below

    • Staging/ restaging/ follow- up of intestinal inflammation
    • Evaluation of known or suspected luminal narrowing/ stricturing disease
    • Evaluation of known or suspected internal penetrating disease

Exclusion criteria

Exclusion Criteria:

  • Undergoing initial imaging for suspected Crohn's disease where the diagnosis of Crohn's disease has yet to be definitively established
  • New Crohn's disease diagnosis, undergoing baseline imaging
  • Isolated colonic disease
  • Known or suspected pregnancy
  • to magnetic resonance imaging (MRI)
  • Ileostomy or prior ileal resection
  • Less than 10 years of age
  • Unable or unwilling to follow imaging procedures
  • Non- English speaking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Crohn's Disease Patients

    Children and adults, who are scheduled for a clinical magnetic resonance enterography (MRE) to evaluate staging/ restaging of Crohn's disease, will be approached to undergo our novel abbreviated MRE. No intervention, observation only, perform MRE, and complete trade-off tolerance survey.

    Diagnostic Test: Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)

Interventions

  • Diagnostic testMagnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)

    Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.

06

What researchers measure

Primary outcomes

  1. Compare clinical MRE with research MRE

    Our abbreviated magnetic resonance enterography (MRE) will be non-inferior to a standard clinical MRE in detecting small bowel inflammation, strictures and penetrating disease associated with Crohn's Disease.

    Time frame: 3 years

Secondary outcomes

  1. Patient experiences and preferences between the abbreviated MRE and the standard clinical MRE.

    Patients/patients parents will answer a survey to determine if the abbreviated magnetic resonance enterography (MRE) or the clinical MRE is preferred.

    Time frame: 3 years

  2. Willingness to trade diagnostic performance for patient experience

    We will ask patients a series of questions to determine their tolerance for trading diagnostic performance for a better patient experience.

    Time frame: 3 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 29 months after the start.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 29 months is below that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 1, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 2028
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533228
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Sep 1, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 27, 2025

Study contacts

Tanita Dean
Contact
Tanita.Dean@cchmc.org
(513) 803-0853
Kristi Cole
Contact
kristi.barnett@cchmc.org
(513)636-9403
Jonathan Dillman
principal investigator · CCHMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion